Navigation Links
NeoStem Signs Stem Cell Collection Agreement With University of Louisville Hospital
Date:5/27/2008

Center to Collect Adult Stem Cells for Storage and to Advance VSEL Research

NEW YORK, May 27 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced that it has signed a collection center agreement with the University of Louisville Hospital/ James Graham Brown Cancer Center.

Robin Smith, MD MBA, NeoStem's Chairman and Chief Executive Officer commented: "This is an extraordinary agreement for NeoStem and University of Louisville that will allow us to move adult stem cell therapies forward, both at the basic science and translational level."

NeoStem acquired the exclusive worldwide rights to Very Small Embryonic-Like (VSEL) Stem Cell technology developed by researchers at the University of Louisville in November 2007. VSELs have been identified in adult bone marrow and resemble embryonic stem cells both morphologically and transcriptionally. Although early stage technology, the Company expects VSELS to serve as the basis for its entry into the therapeutic market place. VSELs have the ability to grow in the laboratory and multiply into clusters of cells that then can differentiate into specialized cells found in different types of tissue including cardiac, neural, endothelial, muscle, pancreatic and hematopoietic cells. However, unlike controversial embryonic stem cells, VSELs can be harvested from adult peripheral blood. These naturally occurring regenerative cells may have the potential to be used for future therapeutic repair of degenerative, diseased or damaged tissue.

"The Louisville collection center represents a unique opportunity for University of Louisville," added Manuel Martinez, M.D., Executive Vice President for Research, University of Louisville. "There are a number of adult stem cell translational scientists and clinicians at the University that are interested in exploring the therapeutic potential of VSELs and other adult stem cells of the body. The collection center will allow harvesting large numbers of these cells from adults donating them for basic research as well as clients paying to have their cells stored for their own future medical need."

"By enabling investigators to have access to large numbers of adult stem cells from interested and informed study subjects, we believe that translational adult stem cell research will move forward at an accelerated pace and that clinical trial designs will be more rapidly implemented to investigate new research findings. Overall, we anticipate that this corporate and academic relationship will assist in propelling the adult stem cell field forward. This will allow NeoStem to take the lead in harnessing and translating this revolutionary and promising new approach to treat human disease."

About NeoStem, Inc.

NeoStem has a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.

Contact:

NeoStem, Inc.

Robin Smith, Chief Executive Officer

T: 212-584-4180

E: rsmith@neostem.com

http://www.neostem.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pot bellies linked to early signs of cardiovascular disease
2. MSU engineering team designs innovative medical device
3. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Gov. Blagojevich Signs Bill Improving Illinois Mental Illness Treatment Law
6. A new technology for cancer screening listens for the signs of cancer
7. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
8. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
9. Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition
10. KARL LAGERFELD SAS Signs Global Eyewear License Agreement With Marchon Eyewear, Inc.
11. MIT Holding, Inc. signs partnership agreement with Georgia Southern University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... 2017 , ... Pivot Point Consulting, a ... the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects of ... clients with initial vendor selection and pre-implementation planning through go-live support and post-live ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a captivating and ... named Edward Koontz. “To Walk Away” is the creation of published author, Larry R. ... two hundred manuscripts in chemistry and religion, as well as four novels. , ...
(Date:8/22/2017)... Carolina (PRWEB) , ... August 22, 2017 , ... ... advisor. Mr. Stewart is the Founder and Managing Member for t4 Leadership Development ... have become critical to his definition of “success”: physician leadership development, servant leadership, ...
(Date:8/21/2017)... Yorba Linda, Ca (PRWEB) , ... August 22, ... ... for numerous industries, but not without risk to health and safety. By learning ... risks could be eliminated. , In this webinar, attendees will gain a ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior assisted living ... Center. , Guests will be able to vote for their favorite Chef among ... with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/31/2017)... MEMPHIS, Tenn. , July 31, 2017 Three Tru-D ... in Yongsan, South Korea . Tru-D, short for "Total ... patient and operating rooms after an environmental services (ES) professional cleans the ... ... "Although ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology: